ClinicalTrials.gg
RecruitingNCT06127407CHONQUERUpdated Oct 28, 2026

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

A Phase 3 interventional study of Ivosidenib 500mg and Placebo in Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen, sponsored by Servier Bio-Innovation LLC. Recruiting at 115 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Servier Bio-Innovation LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Oct 28, 2026Enrollment updatedEligibility revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
370th of 1,863
156 · median 43
Started
2024
with 76 others
Phase 3
164 of 2,054
21 open now
Primary completion
2028-02
later than 360 of 540 live
Registered
1,824th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 370th largest by planned enrollment of the 1,863 interventional ones that give a count, is one of 77 that started in 2024, is one of 164 in phase 3, reaches primary completion later than 360 of the 540 other live ones, and was the 1,824th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must have radiographic progression/recurrence of disease according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and have received 0 to 2 prior systemic treatment regimens in the advanced/metastatic setting for conventional chondrosarcoma. The primary endpoint is progression-free survival (PFS) in Grades 1 and 2 participants. Key secondary endpoints are PFS in all randomized participants, overall survival (OS) in Grades 1 and 2 participants, and OS in all randomized participants.

Participants who meet enrollment criteria will be randomized 1:1 to receive oral ivosidenib 500mg once daily, or a matching placebo once daily.

03

Conditions studied

  • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

Browse trials for

Keywords

  • Conventional chondrosarcoma
  • IDH1
  • ivosidenib
  • locally advanced
  • metastatic
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a histopathological diagnosis consistent with locally advanced or conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection.
  • Have at least one BICR-confirmed as defined by v1.1. Participants who have received prior radiation therapy are eligible provided measurable disease falls outside of the treatment field or within the field and has shown ≥20% growth in size since post-treatment assessment.
  • Have received 0 to 2 prior systemic treatment regimens in the advanced/metastatic setting for chondrosarcoma.
  • Have radiographic progression/recurrence of disease according to RECIST v1.1 defined as:

    1. Radiographic progression of disease (local and/or distant) documented by 2 imaging assessments performed no more than 6 months (±2 weeks) apart within 12 months before randomization.

      OR

    2. Any recurrence of disease (local and/or distant) after complete surgical resection and documented by imaging within 6 months (±2 weeks) before randomization.
  • Have documented IDH1 gene-mutated disease (from a fresh tumor or the most recent banked tumor tissue available that was sourced from either a primary or metastatic tumor lesion) based on central laboratory testing (R132C/L/G/H/S mutation variants tested)
  • Have recovered from any sequelae and toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer.

Exclusion criteria

Exclusion Criteria:

  • Are unable to swallow oral medication.
  • Pregnant or lactating women.
  • Are participating in another interventional study at the same time; participation in noninterventional registries or epidemiological studies is allowed.
  • Have received prior therapy with an IDH1 inhibitor
  • Have received systemic anticancer therapy \<2 weeks prior to randomization (for or immune-based anticancer therapy \<4 weeks).
  • Have received radiotherapy \<2 weeks prior to randomization.
  • Have known symptomatic requiring >10 mg per day prednisone (or equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to randomization, have discontinued or reduced corticosteroid treatment \<=10 mg per day for these for at least 4 weeks and have radiographically stable disease of brain lesions for at least 3 months prior to randomization.
  • Have a history of another primary cancer, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated carcinoma in situ; or c) pT1-2 prostatic cancer Gleason score \<6 or d) participant is free of other primary solid or liquid tumor for ≥ 1 year prior to the start of study treatment and, in the opinion of the Investigator, the disease will not affect participant's outcome in the setting of current chondrosarcoma diagnosis.
  • Have had major surgery within 4 weeks prior to randomization.
  • Have significant active cardiac disease within 6 months prior to randomization, including (NYHA) Class III or IV congestive heart failure; myocardial infarction; unstable angina; and/or stroke.
  • Have \<40% by ECHO scan (or by other methods according to institutional practice) obtained within 28 days prior to randomization.
  • Have a heart-rate interval (using Fridericia's formula) (QTcF) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval syndrome). Participants with a bundle branch block combined with a prolonged QTcF interval may be permitted based on local cardiology assessment.
  • Have known medical history of progressive multifocal leukoencephalopathy (PML).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Ivosidenib

    Taken continuously until BICR-confirmed disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, lost to follow-up, or the Sponsor ends the study (estimated average treatment duration of two years).

    Drug: Ivosidenib 500mg

  • Placebo comparator
    Placebo

    Taken continuously until BICR-confirmed disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, lost to follow-up, or the Sponsor ends the study (estimated average treatment duration of two years). Participants randomized to the placebo arm who experience BICR-confirmed disease progression and meet the crossover eligibility criteria will be given the opportunity to cross over and receive ivosidenib.

    Drug: Placebo

Interventions

  • Provided as tablets, taken orally as two 250mg tablets once daily.

  • DrugPlacebo

    Provided as tablets, taken orally once daily.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) based on Blinded Independent Central Reviewer (BICR) assessment in Grade 1 and Grade 2 participants

    From randomization until BICR confirmed progressive disease or death due to any cause, whichever occurs first

    Time frame: Up to approximately 31 months

Secondary outcomes

  1. PFS based on BICR assessment in all randomized participants

    From randomization until BICR confirmed progressive disease or death due to any cause, whichever occurs first

    Time frame: Up to approximately 31 months

  2. Overall survival (OS) in Grade 1 and Grade 2 participants

    From randomization until death

    Time frame: Up to 5 years

  3. OS in all randomized participants

    From randomization until death

    Time frame: Up to 5 years

  4. PFS based on Investigator assessment in Grade 1 and Grade 2 participants

    From randomization until BICR confirmed progressive disease or death due to any cause, whichever occurs first

    Time frame: Up to approximately 31 months

  5. PFS based on Investigator assessment in all randomized participants

    From randomization until BICR confirmed progressive disease or death due to any cause, whichever occurs first

    Time frame: Up to approximately 31 months

  6. Objective response (OR) (confirmed complete response(CR) or confirmed partial response (PR)) of anti-tumor activity (using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) in Grade 1 and Grade 2 participants

    From randomization until confirmed CR or PR

    Time frame: Up to approximately 31 months

  7. OR (confirmed CR or confirmed PR) of anti-tumor activity (using RECIST v1.1) in all randomized participants

    From randomization until confirmed CR or PR

    Time frame: Up to approximately 31 months

  8. Duration of response (DOR) in Grade 1 and Grade 2 participants

    The time from date of first documented confirmed CR or confirmed PR to date of first documented disease progression or death due to any cause.

    Time frame: Up to approximately 31 months

  9. DOR in all randomized participants

    The time from date of first documented confirmed CR or confirmed PR to date of first documented disease progression or death due to any cause.

    Time frame: Up to approximately 31 months

  10. Time to response (TTR) in Grade 1 and Grade 2 participants

    The time from the date of randomization to date of first documented confirmed complete response (CR) or confirmed partial response (PR).

    Time frame: Up to approximately 31 months

  11. TTR in all randomized participants

    The time from the date of randomization to date of first documented confirmed complete response (CR) or confirmed partial response (PR).

    Time frame: Up to approximately 31 months

  12. Disease control (DC) confirmed CR, confirmed PR, or stable disease (SD)) in Grade 1 and Grade 2 participants

    Time frame: Through the end of the study (a maximum of 5 years after the study start)

  13. DC (confirmed CR, confirmed PR, or SD) in all randomized participants

    Time frame: Through the end of the study (a maximum of 5 years after the study start)

  14. Duration of disease control (DoDC) in Grade 1 and Grade 2 participants

    Time frame: Through the end of the study (a maximum of 5 years after the study start)

  15. DoDC in all randomized participants

    Time frame: Through the end of the study (a maximum of 5 years after the study start)

  16. Number of Adverse Events (AEs)

    Time frame: Through the Safety Follow-up Visit (28-33 days after discontinuation of treatment)

  17. Number of Serious Adverse Events (SAEs)

    Time frame: Through the Safety Follow-up Visit (28-33 days after discontinuation of treatment)

  18. Number of Adverse Events of Special Interest (AESIs)

    Time frame: Through the Safety Follow-up Visit (28-33 days after discontinuation of treatment)

  19. Number of Adverse Events (AEs) leading to discontinuation, treatment interruption, and dose reduction

    Time frame: Through the Safety Follow-up Visit (28-33 days after discontinuation of treatment)

  20. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) score

    The EORTC-QLQ-C30 contains 30 items across 5 functional scales, 9 symptom scales and a global health status. Raw scores are converted to scales ranging from 0 - 100. For the functional scales and global health status, the higher score represents the better functioning or global health status; for the symptom scales, the higher score represents an increase in symptoms.

    Time frame: Through the Safety Follow-up Visit (28-33 days after discontinuation of treatment)

  21. European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) score

    The 5-level EQ-5D-5L scores range from 5 to 25 with a higher number representing a worse health status.

    Time frame: Through the Safety Follow-up Visit (28-33 days after discontinuation of treatment)

  22. Patient-Reported Outcomes Measurement Information System (PROMIS) score

    The PROMIS Item Bank v1.0 Physical Function with Mobility Aid - Short Form questionnaire score ranges from 1 "Unable to do" to 5 "Can do without a problem" for each capability.

    Time frame: Through the Safety Follow-up Visit (28-33 days after discontinuation of treatment)

  23. Ivosidenib concentration in plasma

    Time frame: Through the end of the study (a maximum of 5 years after the study start)

  24. 2-hydroxyglutarate (2-HG) concentration in plasma

    Time frame: Through the end of the study (a maximum of 5 years after the study start)

07

Study locations

111 of 115 sites recruiting

Showing the first 100 of 115 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Tap WD, Cote GM, Burris H, Gore L, Elias A, Beeram M, Conley AP, Gianolio DA, Qu Z, Pandya S, Trent JC. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. Clin Cancer Res. 2025 Jun 3;31(11):2108-2114. doi: 10.1158/1078-0432.CCR-24-4128. PubMed 40100120 ↗

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Feb 2028, 42 months after the start.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's planned 42 months is close to that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Jul 9, 2024
Primary completionEst.
Feb 1, 2028
CompletionEst.
Nov 26, 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 5 sites removed. 3 sites changed recruiting status (3 now terminated)
Show 3 sites
  • Usc Norris Comprehensive Cancer Center · Los Angeles, United StatesRecruiting→Terminated
  • Impar Serviços Hospitalares S.A. - Hospital Nove de Julho · São Paulo, BrazilRecruiting→Terminated
  • Muhc Glen Site · Montreal, CanadaRecruiting→Terminated
Show 6 added (3 Australia, 2 China, 1 France)
  • Chris O'Brien Lifehouse · Camperdown, Australia
  • St Vincent'S Hospital Melbourne · Fitzroy, Australia
  • Sir Charles Gairdner Hospital · Nedlands, Australia
  • Henan Cancer Hospital · Zhengzhou, China
  • Hunan Cancer Hospital · Changsha, China
  • Hôpital de Hautepierre · Strasbourg, France
Show 5 removed
  • Chris O'Brien Lifehouse · Camperdown, Australia
  • St Vincent'S Hospital Melbourne · Fitzroy, Australia
  • Sir Charles Gairdner Hospital · Nedlands, Australia
  • Instituto Nacional Do Câncer - Inca · Rio de Janeiro, Brazil
  • Henan Cancer Hospital · Guangzhou, China
Oct 13, 2026
Enrollment
136→156
Oct 28, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedHave a histopathological diagnosis (fresh or banked tumor biopsy sample collected within the last 3 years) consistent with locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection.
  • EditedHave received 0 or 1to 2 prior systemic treatment regimenregimens in the advanced/metastatic setting for chondrosarcoma.
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Muhc Glen Site · Montreal, CanadaContact removed r•••@ssss.gouv.qc.ca · •••1934Contact removed (no phone or email listed)
Oct 13, 2026
Title
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment RegimenRegimens
Oct 28, 2026
Show all 2 updates
  1. Oct 28, 2026
    Enrollment 136→156
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedHave a histopathological diagnosis (fresh or banked tumor biopsy sample collected within the last 3 years) consistent with locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection.
    • EditedHave received 0 or 1to 2 prior systemic treatment regimenregimens in the advanced/metastatic setting for chondrosarcoma.
    Title Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment RegimenRegimens
    + 1 other change: description
  2. Oct 13, 2026
    6 sites added, 5 sites removed. 3 sites changed recruiting status (3 now terminated)
    Show 3 sites
    • Usc Norris Comprehensive Cancer Center · Los Angeles, United StatesRecruiting→Terminated
    • Impar Serviços Hospitalares S.A. - Hospital Nove de Julho · São Paulo, BrazilRecruiting→Terminated
    • Muhc Glen Site · Montreal, CanadaRecruiting→Terminated
    Show 6 added (3 Australia, 2 China, 1 France)
    • Chris O'Brien Lifehouse · Camperdown, Australia
    • St Vincent'S Hospital Melbourne · Fitzroy, Australia
    • Sir Charles Gairdner Hospital · Nedlands, Australia
    • Henan Cancer Hospital · Zhengzhou, China
    • Hunan Cancer Hospital · Changsha, China
    • Hôpital de Hautepierre · Strasbourg, France
    Show 5 removed
    • Chris O'Brien Lifehouse · Camperdown, Australia
    • St Vincent'S Hospital Melbourne · Fitzroy, Australia
    • Sir Charles Gairdner Hospital · Nedlands, Australia
    • Instituto Nacional Do Câncer - Inca · Rio de Janeiro, Brazil
    • Henan Cancer Hospital · Guangzhou, China
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Muhc Glen Site · Montreal, CanadaContact removed r•••@ssss.gouv.qc.ca · •••1934Contact removed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06127407
Lead sponsor
Servier Bio-Innovation LLC
Collaborators
Institut de Recherches Internationales Servier
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Jul 9, 2024
Primary completion
Feb 1, 2028 (estimated)
Completion
Nov 26, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Contact
scientificinformation@servier.com
+33 1 55 72 60 00

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivosidenib

Start the discussion